QUANTRO Therapeutics Secures Key Austrian Research Grant to Advance Platform Development

Vienna, Austria, 06 August 2024: QUANTRO Therapeutics GmbH has announced receiving an important 18-month research grant from the Austrian Research Promotion Agency (FFG). This funding backs a EUR 1.7 million R&D project aimed at advancing QUANTRO's transcriptomic discovery platform to an industrial level.

The FFG program, supported by Austria's Federal Ministries and other entities, is focused on enhancing QUANTRO’s time-resolved transcriptomic profiling technology. This platform identifies modulators of transcription factors and cell signaling regulators with high precision.

New funds will help QUANTRO scale its platform through miniaturization, automation, and multiplexing. The company intends to develop 10-target screens, enabling simultaneous screening of multiple drug candidates, thus setting a new standard in drug discovery.

CEO Michael Bauer expressed that the grant will allow the company to explore multiple targets with advanced bioinformatics solutions. Arianna Sabò, Head of Research, noted the grant will expand their technology, particularly for previously 'undruggable' targets.